SAB Biotherapeutics Inc. (SABS)
NASDAQ: SABS · IEX Real-Time Price · USD
1.92
-0.12 (-5.88%)
May 20, 2022 4:30 PM EDT - Market closed
Income Statement (Quarterly)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Quarter Ended | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|
| Revenue | 11.8 | 11.06 | 14.68 | - | 16.93 | 25.76 | 17.47 |
| Revenue Growth (YoY) | -30.27% | -57.06% | -15.96% | - | - | - | - |
| Gross Profit | 11.8 | 11.06 | 14.68 | - | 16.93 | 25.76 | 17.47 |
| Selling, General & Admin | 5.19 | 7.75 | 3.6 | - | 3.33 | 1.86 | 2.5 |
| Research & Development | 13.32 | 10.65 | 15.07 | - | 12.78 | 15.31 | 5.02 |
| Operating Expenses | 18.51 | 18.4 | 18.67 | - | 16.11 | 17.17 | 7.52 |
| Operating Income | -6.71 | -7.34 | -3.99 | - | 0.81 | 8.58 | 9.95 |
| Interest Expense / Income | 0.07 | 0.07 | 0.08 | - | 0.08 | 0.14 | 0.03 |
| Other Expense / Income | -7.86 | 4.14 | -0 | 0 | -0.67 | -0.01 | -0.01 |
| Pretax Income | 1.08 | -11.55 | -4.06 | 0 | 1.41 | 8.44 | 9.93 |
| Income Tax | 0.09 | 0 | 0 | - | 0 | 0 | 0 |
| Net Income | 0.99 | -11.55 | -4.06 | - | 1.41 | 8.44 | 9.93 |
| Net Income Common | 0.99 | -11.55 | -4.06 | - | 1.41 | 8.44 | 9.93 |
| Net Income Growth | -30.07% | - | - | - | - | - | - |
| Shares Outstanding (Basic) | 43 | 27 | 35 | 35 | 26 | 25 | 35 |
| Shares Outstanding (Diluted) | 46 | 27 | 35 | - | 28 | 27 | 60 |
| Shares Change | 63.21% | 1.21% | -41.21% | - | - | - | - |
| EPS (Basic) | 0.02 | -0.47 | -0.12 | - | 0.05 | 0.57 | 0.19 |
| EPS (Diluted) | 0.02 | -0.47 | -0.12 | - | 0.05 | 0.54 | 0.17 |
| EPS Growth | -60.00% | - | - | - | - | - | - |
| Free Cash Flow Per Share | -0.27 | -0.20 | 0.02 | - | 0.29 | -0.03 | -0.01 |
| Gross Margin | 100.00% | 100.00% | 100.00% | - | 100.00% | 100.00% | 100.00% |
| Operating Margin | -56.83% | -66.41% | -27.16% | - | 4.81% | 33.32% | 56.97% |
| Profit Margin | 8.35% | -104.46% | -27.66% | - | 8.33% | 32.79% | 56.82% |
| Free Cash Flow Margin | -98.06% | -49.45% | 3.88% | - | 44.68% | -3.18% | -2.84% |
| Effective Tax Rate | 8.56% | 0.00% | 0.00% | - | 0.00% | 0.00% | 0.00% |
| EBITDA | 1.83 | -10.82 | -3.57 | - | 1.76 | 8.79 | 10.1 |
| EBITDA Margin | 15.48% | -97.88% | -24.30% | - | 10.41% | 34.12% | 57.81% |
| EBIT | 1.15 | -11.49 | -3.98 | - | 1.49 | 8.59 | 9.96 |
| EBIT Margin | 9.74% | -103.86% | -27.13% | - | 8.77% | 33.34% | 57.01% |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).